Your browser doesn't support javascript.
loading
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.
Geerts, Paulus A F; 't Hart, Nils; Visser, Otto; Ortiz-Maldonado, Valentín; Chamuleau, Martine E D.
Afiliação
  • Geerts PAF; Department of Internal Medicine Isala Klinieken Zwolle Netherlands.
  • 't Hart N; Department of Pathology Isala Klinieken Zwolle Netherlands.
  • Visser O; Department of Internal Medicine Isala Klinieken Zwolle Netherlands.
  • Ortiz-Maldonado V; Department of Hematology Hospital Clínic de Barcelona Barcelona Spain.
  • Chamuleau MED; Department of Hematology Amsterdam University Medical Centre Amsterdam Netherlands.
Clin Case Rep ; 11(6): e7361, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37260617
Key Clinical Message: The prognosis of patients with relapsed or refractory (R/R) BL is poor with limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. Novel therapies may be promising but need refinement. Abstract: The prognosis of patients with relapsed or refractory (R/R) BL is poor with a limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. We present three cases of patients with R/R BL receiving novel therapies followed by a literature review. Amongst others, the patients received inotuzumab ozogamicin, idelalisib, ibrutinib, and CAR-T cell therapy, however, with limited response. In literature, response to several novel agents is described; however, most promising results are seen with CAR-T cell therapy. Concluding from case series, sequential CAR-T cell therapy, targeting multiple B-cell antigens, seems most promising.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article